D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$862M |
| 2 |
Baidu
BIDU
|
+$752M |
| 3 |
Tencent Music
TME
|
+$426M |
| 4 |
Coca-Cola
KO
|
+$424M |
| 5 |
NVIDIA
NVDA
|
+$383M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$981M |
| 2 |
Wells Fargo
WFC
|
+$673M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$574M |
| 4 |
Moderna
MRNA
|
+$442M |
| 5 |
DuPont de Nemours
DD
|
+$415M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.93% |
| 2 | Consumer Discretionary | 10.48% |
| 3 | Healthcare | 8.56% |
| 4 | Communication Services | 8.41% |
| 5 | Financials | 6.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2751
CEVA Inc
CEVA
$897M
| $1.33M | ﹤0.01% |
23,727
-44,510
| -65% | -$2.65M |
|
2752
International Paper
IP
$23.3B
| $1.33M | ﹤0.01% |
26,002
+21,164
| +437% | +$1.03M |
|
|
PLAN
2753
PUT
DELISTED
Anaplan, Inc.
PLAN
| $1.33M | ﹤0.01% |
+24,700
| New | +$1.67M |
|
|
NRACU
2754
DELISTED
Northern Revival Acquisition Corporation Unit
NRACU
| $1.33M | ﹤0.01% |
+134,442
| New | +$1.36M |
|
2755
Nutanix
NTNX
$16.1B
| $1.33M | ﹤0.01% |
+49,995
| New | +$1.52M |
|
2756
Customers Bancorp
CUBI
$2.68B
| $1.33M | ﹤0.01% |
41,718
+10,794
| +35% | +$284K |
|
2757
Regional Management Corp
RM
$396M
| $1.32M | ﹤0.01% |
38,241
-6,963
| -15% | -$227K |
|
2758
CALL
Xylem
XYL
$29.6B
| $1.32M | ﹤0.01% |
+12,600
| New | +$1.28M |
|
|
RUBY
2759
CALL
DELISTED
Rubius Therapeutics, Inc
RUBY
| $1.32M | ﹤0.01% |
+50,000
| New | +$730K |
|
2760
National Grid
NGG
$81.6B
| $1.32M | ﹤0.01% |
+25,252
| New | +$1.32M |
|
|
ACKIU
2761
DELISTED
Ackrell SPAC Partners I Co Units
ACKIU
| $1.32M | ﹤0.01% |
130,358
-29,642
| -19% | -$309K |
|
2762
CALL
NovoCure
NVCR
$1.92B
| $1.32M | ﹤0.01% |
10,000
-10,900
| -52% | -$1.72M |
|
|
2763
PUT
NovoCure
NVCR
$1.92B
| $1.32M | ﹤0.01% |
10,000
-9,500
| -49% | -$1.5M |
|
2764
Kilroy Realty
KRC
$4.47B
| $1.32M | ﹤0.01% |
20,132
-283,355
| -93% | -$17.5M |
|
2765
Joby Aviation
JOBY
$7.1B
| $1.32M | ﹤0.01% |
130,071
-137,552
| -51% | -$1.67M |
|
|
TIGR
2766
UP Fintech Holding
TIGR
$858M
| $1.32M | ﹤0.01% |
74,073
-748,502
| -91% | -$15.2M |
|
2767
Cameco
CCJ
$37.6B
| $1.32M | ﹤0.01% |
79,213
-1,149,514
| -94% | -$17.7M |
|
2768
Castle Biosciences
CSTL
$739M
| $1.31M | ﹤0.01% |
19,153
+64
| +0.3% | +$4.81K |
|
2769
First Bancorp
FBNC
$2.65B
| $1.31M | ﹤0.01% |
30,017
-2,619
| -8% | -$104K |
|
2770
Darling Ingredients
DAR
$9.33B
| $1.3M | ﹤0.01% |
+17,633
| New | +$1.21M |
|
2771
UGI
UGI
$7.98B
| $1.29M | ﹤0.01% |
31,569
-123,438
| -80% | -$4.77M |
|
2772
Kodiak Sciences
KOD
$2.44B
| $1.29M | ﹤0.01% |
+11,391
| New | +$1.56M |
|
2773
Nurix Therapeutics
NRIX
$2.44B
| $1.28M | ﹤0.01% |
+41,198
| New | +$1.56M |
|
2774
CALL
Centene
CNC
$31.4B
| $1.28M | ﹤0.01% |
+20,000
| New | +$1.24M |
|
2775
IAMGOLD
IAG
$8.21B
| $1.28M | ﹤0.01% |
428,732
+151,086
| +54% | +$500K |
|
Similar funds
D.E. Shaw & Co's Q1 2021 Portfolio in Review
As of Q1 2021, D.E. Shaw & Co held 4,712 positions worth $104B, down 7.4% from $112B the previous quarter. Its ten largest holdings account for 9.9% of the portfolio.
D.E. Shaw & Co withdrew a net $18.3B in Q1 2021, closing 730 positions and reducing 1,773 holdings. Its most notable exit was AstraZeneca, an estimated $214M position sold in full.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 14% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, D.E. Shaw & Co opened a new position in Baidu worth $627M.
- D.E. Shaw & Co's largest Q1 2021 buy was Baidu: 2,881,724 shares worth $627M.
- D.E. Shaw & Co added most to Tesla in Q1 2021, an estimated $862M increase.
- D.E. Shaw & Co's biggest Q1 2021 reduction was Amazon, cutting an estimated $981M.
- D.E. Shaw & Co fully exited AstraZeneca in Q1 2021, selling an estimated $214M.
- D.E. Shaw & Co's ten largest holdings make up 9.9% of its $104B portfolio in Q1 2021.
- D.E. Shaw & Co opened 825 new positions and closed 730 in Q1 2021.
- D.E. Shaw & Co's portfolio value fell 7.4% quarter-over-quarter to $104B.
Based on D.E. Shaw & Co's 13F filing for Q1 2021, filed 17 May 2021.